Medicare to Offer Discounted GLP-1 Weight Loss Drugs for $50 Copay

The Centers for Medicare & Medicaid Services (CMS) has announced a new time-limited demonstration program designed to expand access to weight-loss medications for eligible seniors. The initiative, known as the Medicare GLP-1 Bridge, will allow qualifying beneficiaries to access specific GLP-1 medications for a monthly cost of $50.

The program is scheduled to begin on July 1, 2026, and will run through December 31, 2027. This demonstration reflects a significant shift in policy, as Medicare has long been barred from covering treatments specifically for weight loss.

Program Eligibility and Logistics

To participate in the Medicare GLP-1 Bridge, individuals must be enrolled in a Medicare Part D prescription drug plan. The program is designed to provide a predictable and affordable cost for evidence-based weight-loss treatments that have previously been prohibitively expensive for many beneficiaries.

The demonstration operates under the authority of the Secretary to test new approaches to care delivery within Medicare. To support this, CMS is implementing centralized processes for payment to pharmacies and claims adjudication.

Covered Medications

The Medicare GLP-1 Bridge will provide coverage for a specific set of GLP-1 medications approved for weight loss. The eligible treatments include:

• Wegovy, available in both pill and injectable formulations.
• Zepbound, specifically the KwikPen formulation.
• Foundayo, available in pill form.

Addressing Financial Barriers to Care

The introduction of the $50 monthly copay addresses a substantial financial gap for seniors. Without insurance coverage, the cash prices for these medications typically range from $149 to $699 per month.

The need for such a program is highlighted by data from KFF polling, which found that about half of GLP-1 users reported that these drugs were difficult to afford. A quarter of those users described the cost as very difficult to manage.

These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost. The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible, while advancing our broader goal of helping Americans live healthier lives.

Dr. Mehmet Oz, CMS Administrator

Public Health Impact and Objectives

CMS officials have emphasized that these medications can be life-changing for patients who are managing obesity and other related health conditions. By reducing the cost barrier, the agency aims to improve long-term health outcomes and quality of life for the elderly population.

GLP-1s can be life-changing for patients managing obesity and related conditions. This demonstration is designed to make accessing those medications simpler, more predictable, and more consistent across the Medicare program, which means better quality of life for seniors and better value across the health care system.

Chris Klomp, Director of Medicare and Chief Counselor at the U.S. Department of Health and Human Services

The Path Toward Long-Term Coverage

The Medicare GLP-1 Bridge is explicitly designed as a short-term pilot. Its primary purpose is to serve as a bridge to fill the gap before a potential longer-term program is established.

While the current demonstration concludes on December 31, 2027, CMS is using this period to evaluate the impact of the coverage. A more permanent program may or may not begin in 2028, depending on the results of this pilot and further policy decisions.